Global Crisaborole Market Size By Type (Purity ?98%, Purity ?98%), By Application (Allergic Dermatitis, Other), By Region, And Segment Forecasts, 2023 to 2032

The Global Crisaborole Market was valued at USD 680 million in 2023 and is projected to reach USD 1.35 billion by 2031, growing at a CAGR of 9.2% during the forecast period from 2023 to 2031. The growth of the global crisaborole market is primarily driven by the increasing prevalence of atopic dermatitis (eczema), rising awareness regarding topical phosphodiesterase-4 (PDE4) inhibitors, and favorable regulatory approvals for new dermatological treatments. Crisaborole, a non-steroidal topical anti-inflammatory medication, is witnessing significant adoption due to its efficacy and favorable safety profile in the treatment of mild to moderate atopic dermatitis in adults and children.

Drivers:

Rising Prevalence of Atopic Dermatitis

The growing incidence of atopic dermatitis across both developed and developing economies is a key driver. Environmental factors, allergens, and increasing pollution levels are contributing to higher eczema cases, fueling the demand for effective treatments like crisaborole.

Growing Awareness and Demand for Non-Steroidal Treatments

Patients are increasingly seeking steroid-free alternatives for long-term skin condition management due to side effects associated with corticosteroids. Crisaborole’s positioning as a non-steroidal anti-inflammatory solution aligns with this demand.

Favorable Regulatory Approvals

Regulatory authorities like the U.S. FDA and EMA have granted approvals for crisaborole-based formulations, enabling broader commercial availability and enhanced market penetration.

Restraints:

High Cost of Treatment

The premium pricing of crisaborole-based products remains a major barrier, limiting accessibility for patients, especially in low- and middle-income countries.

Availability of Alternative Treatments

Availability of other topical therapies, including corticosteroids, calcineurin inhibitors, and emerging biologics, presents competitive challenges to crisaborole adoption.

Opportunity:

Expansion in Emerging Markets

Pharmaceutical companies are increasingly targeting emerging regions like Asia-Pacific and Latin America for the introduction of crisaborole, supported by growing healthcare expenditure and awareness campaigns.

Development of Combination Therapies

Ongoing research in combining crisaborole with other dermatological agents for enhanced therapeutic outcomes presents lucrative opportunities for market players.

Market by System Type Insights:

Based on product formulation, the ointment segment dominated the market in 2023, owing to its established efficacy in dermatological applications. However, the cream-based formulation segment is expected to witness the highest growth during the forecast period, driven by increasing consumer preference for non-greasy and easily absorbable topical solutions.

Market by End-use Insights:

The hospital pharmacies segment accounted for the largest market share in 2023, driven by prescription-driven sales of crisaborole formulations. Online pharmacies are projected to register the highest growth rate, supported by increasing digitalization of healthcare services and the growing popularity of e-commerce platforms for dermatological products.

Market by Regional Insights:

North America dominated the global crisaborole market in 2023, backed by the high prevalence of atopic dermatitis, advanced healthcare infrastructure, and early adoption of new therapies. Asia-Pacific is expected to exhibit the fastest growth rate during the forecast period, driven by rising awareness, increasing patient pool, and expanding healthcare access in countries such as China and India.

Competitive Scenario:

Prominent players operating in the global crisaborole market include Pfizer Inc., Sun Pharmaceutical Industries Ltd., Anacor Pharmaceuticals, Inc., Encore Dermatology, Inc., and Medimetriks Pharmaceuticals, Inc. Companies are focusing on strategic collaborations, regulatory approvals, and product portfolio expansion to strengthen their market presence.

Key Market Developments:

In 2023, Pfizer Inc. announced the expansion of its crisaborole product availability in select Asian markets, targeting growing demand for non-steroidal topical treatments.

In 2022, Sun Pharmaceutical Industries Ltd. launched a generic version of crisaborole ointment in select Latin American countries to expand its dermatology portfolio.

In 2021, Medimetriks Pharmaceuticals, Inc. entered into a strategic licensing agreement for crisaborole formulation enhancements aimed at improving patient compliance and therapeutic outcomes.

Scope of Work – Global Crisaborole Market

Report Metric Details

Market Size (2023) USD 680 Million

Projected Market Size (2031) USD 1.35 Billion

CAGR (2023-2031) 9.2%

Key Segments by Product Type Ointment, Cream

Key Segments by End-Use Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Leading Region North America

Key Players Pfizer Inc., Sun Pharmaceutical Industries Ltd., Anacor Pharmaceuticals, Inc., Encore Dermatology, Inc., Medimetriks Pharmaceuticals, Inc.

FAQs – Global Crisaborole Market

1) What is the current market size of the Global Crisaborole Market?

The Global Crisaborole Market was valued at USD 680 million in 2023.

2) What is the major growth driver of the Global Crisaborole Market?

The increasing prevalence of atopic dermatitis and rising demand for non-steroidal topical treatments are the major growth drivers.

3) Which is the largest region during the forecast period in the Global Crisaborole Market?

North America is expected to remain the largest region during the forecast period due to advanced healthcare infrastructure and high disease prevalence.

4) Which segment accounted for the largest market share in the Global Crisaborole Market?

The ointment segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Crisaborole Market?

Key players include Pfizer Inc., Sun Pharmaceutical Industries Ltd., Anacor Pharmaceuticals, Inc., Encore Dermatology, Inc., and Medimetriks Pharmaceuticals, Inc.

Would you like me to create a visually formatted report document for this content?